TheraRNA key facts
as of Oct 2026- Manufacturer of mRNA vaccine drugs designed to treat infectious diseases and cancers.
- TheraRNA is valued at approximately $27.9M as of Oct 2026 (last reported valuation).
- It has raised $6.4M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Oriental Fortune Capital, Shenzhen Weltrust Investment Co., CrowdBees, Share Capital.
- Status: Privately Held (backing).
TheraRNA's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·Watch TheraRNA: the Monday email on marks, rounds and moves
TheraRNA funding rounds
No funding rounds for TheraRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
TheraRNA valuation
TheraRNA's last reported valuation was $27.9 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
TheraRNA investors
4 investors are on record for TheraRNA, including Oriental Fortune Capital, Shenzhen Weltrust Investment Co., CrowdBees and Share Capital.
About TheraRNA
Manufacturer of mRNA vaccine drugs designed to treat infectious diseases and cancers. The company offers proprietary lipid nanoparticle delivery technology and scalable mRNA production capabilities, enabling pharmaceutical companies, healthcare providers and research institutions to deliver affordable and effective vaccines to patients.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2019
- Employees
- 4
- Website
- therarna.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.